Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension

Rita Papp, Chandran Nagaraj, Diana Zabini, Bence M. Nagy, Miklós Lengyel, Davor Skofic Maurer, Neha Sharma, Bakytbek Egemnazarov, Gabor Kovacs, Grazyna Kwapiszewska, Leigh M. Marsh, Andelko Hrzenjak, Gerald Höfler, Miroslava Didiasova, Malgorzata Wygrecka, Laura K. Sievers, Peter Szucs, P. Enyedi, Bahil Ghanim, Walter Klepetko & 2 others Horst Olschewski, Andrea Olschewski

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Our systematic analysis of anion channels and transporters in idiopathic pulmonary arterial hypertension (IPAH) showed marked upregulation of the Cl- channel TMEM16A gene. We hypothesised that TMEM16A overexpression might represent a novel vicious circle in the molecular pathways causing pulmonary arterial hypertension (PAH). We investigated healthy donor lungs (n=40) and recipient lungs with IPAH (n=38) for the expression of anion channel and transporter genes in small pulmonary arteries and pulmonary artery smooth muscle cells (PASMCs). In IPAH, TMEM16A was strongly upregulated and patch-clamp recordings confirmed an increased Cl- current in PASMCs (n=9-10). These cells were depolarised and could be repolarised by TMEM16A inhibitors or knock-down experiments (n=6-10). Inhibition/knock-down of TMEM16A reduced the proliferation of IPAH-PASMCs (n=6). Conversely, overexpression of TMEM16A in healthy donor PASMCs produced an IPAH-like phenotype. Chronic application of benzbromarone in two independent animal models significantly decreased right ventricular pressure and reversed remodelling of established pulmonary hypertension. Our findings suggest that increased TMEM16A expression and activity comprise an important pathologic mechanism underlying the vasoconstriction and remodelling of pulmonary arteries in PAH. Inhibition of TMEM16A represents a novel therapeutic approach to reverse remodelling in PAH.

Original languageEnglish
Article number1800965
JournalEuropean Respiratory Journal
Volume53
Issue number6
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

Vasoconstriction
Pulmonary Artery
Pulmonary Hypertension
Smooth Muscle Myocytes
Anions
Benzbromarone
Lung
Ventricular Pressure
Genes
Familial Primary Pulmonary Hypertension
Up-Regulation
Animal Models
Phenotype

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Papp, R., Nagaraj, C., Zabini, D., Nagy, B. M., Lengyel, M., Maurer, D. S., ... Olschewski, A. (2019). Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 53(6), [1800965]. https://doi.org/10.1183/13993003.00965-2018

Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension. / Papp, Rita; Nagaraj, Chandran; Zabini, Diana; Nagy, Bence M.; Lengyel, Miklós; Maurer, Davor Skofic; Sharma, Neha; Egemnazarov, Bakytbek; Kovacs, Gabor; Kwapiszewska, Grazyna; Marsh, Leigh M.; Hrzenjak, Andelko; Höfler, Gerald; Didiasova, Miroslava; Wygrecka, Malgorzata; Sievers, Laura K.; Szucs, Peter; Enyedi, P.; Ghanim, Bahil; Klepetko, Walter; Olschewski, Horst; Olschewski, Andrea.

In: European Respiratory Journal, Vol. 53, No. 6, 1800965, 01.06.2019.

Research output: Contribution to journalArticle

Papp, R, Nagaraj, C, Zabini, D, Nagy, BM, Lengyel, M, Maurer, DS, Sharma, N, Egemnazarov, B, Kovacs, G, Kwapiszewska, G, Marsh, LM, Hrzenjak, A, Höfler, G, Didiasova, M, Wygrecka, M, Sievers, LK, Szucs, P, Enyedi, P, Ghanim, B, Klepetko, W, Olschewski, H & Olschewski, A 2019, 'Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension', European Respiratory Journal, vol. 53, no. 6, 1800965. https://doi.org/10.1183/13993003.00965-2018
Papp, Rita ; Nagaraj, Chandran ; Zabini, Diana ; Nagy, Bence M. ; Lengyel, Miklós ; Maurer, Davor Skofic ; Sharma, Neha ; Egemnazarov, Bakytbek ; Kovacs, Gabor ; Kwapiszewska, Grazyna ; Marsh, Leigh M. ; Hrzenjak, Andelko ; Höfler, Gerald ; Didiasova, Miroslava ; Wygrecka, Malgorzata ; Sievers, Laura K. ; Szucs, Peter ; Enyedi, P. ; Ghanim, Bahil ; Klepetko, Walter ; Olschewski, Horst ; Olschewski, Andrea. / Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension. In: European Respiratory Journal. 2019 ; Vol. 53, No. 6.
@article{f3a23d4feb1245369edeb961abe9072e,
title = "Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension",
abstract = "Our systematic analysis of anion channels and transporters in idiopathic pulmonary arterial hypertension (IPAH) showed marked upregulation of the Cl- channel TMEM16A gene. We hypothesised that TMEM16A overexpression might represent a novel vicious circle in the molecular pathways causing pulmonary arterial hypertension (PAH). We investigated healthy donor lungs (n=40) and recipient lungs with IPAH (n=38) for the expression of anion channel and transporter genes in small pulmonary arteries and pulmonary artery smooth muscle cells (PASMCs). In IPAH, TMEM16A was strongly upregulated and patch-clamp recordings confirmed an increased Cl- current in PASMCs (n=9-10). These cells were depolarised and could be repolarised by TMEM16A inhibitors or knock-down experiments (n=6-10). Inhibition/knock-down of TMEM16A reduced the proliferation of IPAH-PASMCs (n=6). Conversely, overexpression of TMEM16A in healthy donor PASMCs produced an IPAH-like phenotype. Chronic application of benzbromarone in two independent animal models significantly decreased right ventricular pressure and reversed remodelling of established pulmonary hypertension. Our findings suggest that increased TMEM16A expression and activity comprise an important pathologic mechanism underlying the vasoconstriction and remodelling of pulmonary arteries in PAH. Inhibition of TMEM16A represents a novel therapeutic approach to reverse remodelling in PAH.",
author = "Rita Papp and Chandran Nagaraj and Diana Zabini and Nagy, {Bence M.} and Mikl{\'o}s Lengyel and Maurer, {Davor Skofic} and Neha Sharma and Bakytbek Egemnazarov and Gabor Kovacs and Grazyna Kwapiszewska and Marsh, {Leigh M.} and Andelko Hrzenjak and Gerald H{\"o}fler and Miroslava Didiasova and Malgorzata Wygrecka and Sievers, {Laura K.} and Peter Szucs and P. Enyedi and Bahil Ghanim and Walter Klepetko and Horst Olschewski and Andrea Olschewski",
year = "2019",
month = "6",
day = "1",
doi = "10.1183/13993003.00965-2018",
language = "English",
volume = "53",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "6",

}

TY - JOUR

T1 - Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension

AU - Papp, Rita

AU - Nagaraj, Chandran

AU - Zabini, Diana

AU - Nagy, Bence M.

AU - Lengyel, Miklós

AU - Maurer, Davor Skofic

AU - Sharma, Neha

AU - Egemnazarov, Bakytbek

AU - Kovacs, Gabor

AU - Kwapiszewska, Grazyna

AU - Marsh, Leigh M.

AU - Hrzenjak, Andelko

AU - Höfler, Gerald

AU - Didiasova, Miroslava

AU - Wygrecka, Malgorzata

AU - Sievers, Laura K.

AU - Szucs, Peter

AU - Enyedi, P.

AU - Ghanim, Bahil

AU - Klepetko, Walter

AU - Olschewski, Horst

AU - Olschewski, Andrea

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Our systematic analysis of anion channels and transporters in idiopathic pulmonary arterial hypertension (IPAH) showed marked upregulation of the Cl- channel TMEM16A gene. We hypothesised that TMEM16A overexpression might represent a novel vicious circle in the molecular pathways causing pulmonary arterial hypertension (PAH). We investigated healthy donor lungs (n=40) and recipient lungs with IPAH (n=38) for the expression of anion channel and transporter genes in small pulmonary arteries and pulmonary artery smooth muscle cells (PASMCs). In IPAH, TMEM16A was strongly upregulated and patch-clamp recordings confirmed an increased Cl- current in PASMCs (n=9-10). These cells were depolarised and could be repolarised by TMEM16A inhibitors or knock-down experiments (n=6-10). Inhibition/knock-down of TMEM16A reduced the proliferation of IPAH-PASMCs (n=6). Conversely, overexpression of TMEM16A in healthy donor PASMCs produced an IPAH-like phenotype. Chronic application of benzbromarone in two independent animal models significantly decreased right ventricular pressure and reversed remodelling of established pulmonary hypertension. Our findings suggest that increased TMEM16A expression and activity comprise an important pathologic mechanism underlying the vasoconstriction and remodelling of pulmonary arteries in PAH. Inhibition of TMEM16A represents a novel therapeutic approach to reverse remodelling in PAH.

AB - Our systematic analysis of anion channels and transporters in idiopathic pulmonary arterial hypertension (IPAH) showed marked upregulation of the Cl- channel TMEM16A gene. We hypothesised that TMEM16A overexpression might represent a novel vicious circle in the molecular pathways causing pulmonary arterial hypertension (PAH). We investigated healthy donor lungs (n=40) and recipient lungs with IPAH (n=38) for the expression of anion channel and transporter genes in small pulmonary arteries and pulmonary artery smooth muscle cells (PASMCs). In IPAH, TMEM16A was strongly upregulated and patch-clamp recordings confirmed an increased Cl- current in PASMCs (n=9-10). These cells were depolarised and could be repolarised by TMEM16A inhibitors or knock-down experiments (n=6-10). Inhibition/knock-down of TMEM16A reduced the proliferation of IPAH-PASMCs (n=6). Conversely, overexpression of TMEM16A in healthy donor PASMCs produced an IPAH-like phenotype. Chronic application of benzbromarone in two independent animal models significantly decreased right ventricular pressure and reversed remodelling of established pulmonary hypertension. Our findings suggest that increased TMEM16A expression and activity comprise an important pathologic mechanism underlying the vasoconstriction and remodelling of pulmonary arteries in PAH. Inhibition of TMEM16A represents a novel therapeutic approach to reverse remodelling in PAH.

UR - http://www.scopus.com/inward/record.url?scp=85067373440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067373440&partnerID=8YFLogxK

U2 - 10.1183/13993003.00965-2018

DO - 10.1183/13993003.00965-2018

M3 - Article

VL - 53

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 6

M1 - 1800965

ER -